A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

NCT05338619 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage III
EGFR Positive Non-small Cell Lung Cancer
Non-squamous Non-small-cell Lung Cancer

Interventions

DRUG: Lazertinib

Sponsor

Sung Yong Lee

Collaborators

[object Object]